Introduction 46
Malaria, caused by Plasmodium falciparum, is one of the most pernicious parasitic diseases, mostly affecting children and pregnant women in sub-Saharan Africa (2, 20). For 48 many decades chloroquine, arguably the safest, most affordable, and globally available anti- 
57
However, there is still consensus on the benefits of SP in intermittent preventive treatment
58
(IPT) programs for infants, pregnant women, and, to a lesser extent, children (18, 41).
59
The aim of IPT is to reduce the frequency of malaria episodes without preventing 60 every blood stage infection. IPT offers protection by clearance of pre-existing, mostly 61 asymptomatic, infections, followed by a short period of post-treatment chemoprophylaxis (41) 62 and permits the natural acquisition of immunity against the pathogenic blood stages (38) .
63
Thereby, IPT avoids the rebound effect that was initially seen in extended continuous 
79
The inhibitory effect of the antifolate drug pyrimethamine on hepatic stages of the 80 malaria parasite was first described more than four decades ago by direct and indirect 81 observations (8, 24) . In this study we wanted to test whether causal prophylaxis with 82 pyrimethamine during inoculation of mice with sporozoites can generate immune-mediated 83 protection against challenge with sporozoites when the drug is no longer present. Secondly,
84
we studied the prophylactic efficacy of pyrimethamine against a pyrimethamine-resistant
85
Plasmodium strain and the effect of pyrimethamine-resistance on potential secondary,
86
immune-mediated protection against reinfection with sporozoites (38 
144
We first established that oral pyrimethamine treatment of C57bl/6 mice within the first 145 42 hours after intravenous application of 10,000 Plasmodium berghei ANKA sporozoites 146 prevented asexual blood stage infection even after prolonged monitoring (0/9), whereas 147 untreated controls showed parasitemia at day 3 after sporozoite inoculation (4/4) (Fig. 1A) 
181
Protection is long-lasting and liver stage-specific
182
We next re-challenged protected mice 5 months after the last challenge by 183 intravenous injection of 10,000 P. berghei ANKA sporozoites (Table 1 ). All control animals 184 became positive at day 3 (n=5) and 4 out of 5 mice developed symptoms of cerebral malaria 185 7 days after challenge. In the test group, all previously exposed mice remained sterilely 186 protected against re-challenge with the homologous P. berghei ANKA strain (n=9). We 187 conclude that pyrimethamine-mediated ablation of liver stage development has the potential 188 to induce lasting protection, similar to an equivalent protocol with primaquine (32).
189
To test whether sterile protection elicited by the sporozoite/pyrimethamine regimen is 190 liver stage-specific, we infected 3 protected animals with 7,500 P. berghei ANKA-infected red 191 blood cells (Table 1) (Fig. 2B ).
213
We next tested whether three inoculation/prophylaxis immunizations with higher 214 mosquito numbers (11-15 bites/mouse) would increase the degree of protection against 215 reinfection. The challenge with 5-10 infected mosquitoes was carried out 40 days after the 216 last immunization (Fig. 2A) . Simultaneously increasing the immunization dose and 217 decreasing the challenge dose resulted in substantial protection. In this experiment, 4 out of 218 5 animals stayed parasitemia-free whereas all controls became patent three days after 219 exposure to infected mosquito bites and subsequently, developed cerebral malaria (Fig. 2B) . 
239
We infected mice with either 25,000 wild type (WT) sporozoites or 25,000 sporozoites 
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Pb18S rRNA transcript levels to assess hepatic parasite burden (Fig. 3D) . We detected a 249 significant 80% reduction of the relative parasite burden in livers of pyrimethamine-treated 250 animals that were infected with the pyrimethamine-resistant parasites compared to WT 251 inoculations (unpaired t-test; P=0.03).
252
We next studied the causal prophylactic activity of pyrimethamine against the sera1 (-) 
253
clone by determining the time to blood stage patency in treated (70 µg/ml) vs. untreated mice 254 (n=5, each) (Fig. 3A) . As previously reported (32), the time to patency in untreated control 
258
infected with wild type parasites remained blood stage parasite-negative (Figs. 1A, 3A) . We 259 also confirmed this finding in vitro in cultured hepatoma cells (Fig. 3B, C) . Exposure of pre- (Fig. 3 and 4) .
300
Although not a focus of this study, the protection observed after repeated inoculations 301 with wild type sporozoites during administration of oral pyrimethamine, appears to be akin to 302 the immunological mechanism and degree of protection afforded by irradiated sporozoites,
303
by certain genetically-modified sporozoites, or by primaquine/sporozoite 'immunization'.
304
Using these attenuation protocols, sporozoites are able to glide and invade, but growth arrest 
310
( Fig. 1 and 3 ). This could be explained by the inhibitory effect of the antifolate drug 311 pyrimethamine on DNA synthesis. We do not know whether and for how long pyrimethamine- 
523
Relative expression levels of the Pb18S gene were normalized to the mouse GAPDH gene. 
552
(A) Animals (N=18) were infected with pyrimethamine-resistant (N=13) and -sensitive (N=5)
553
sporozoites under suboptimal pyrimethamine cover. All animals were monitored for 554 parasitemia and cured with 1.6 mg/day chloroquine for 7 days, starting at day 14. 14 animals
555
developed parasitemia between day 3 and 10 after infection, and 4 stayed malaria-free. All 
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